by PARP inhibitor biomarkers play a pivotal role in the development of personalized medicine for cancer treatment. Targeting specific DNA repair pathways has revolutionized cancer therapeutics. PARP inhibitor biomarkers help detect homologous recombination deficiency (HRD) in tumors, which indicates sensitivity to PARP inhibitors. Several PARP inhibitors have been approved or are in clinical trials for various cancer types like ovarian cancer and breast cancer. The identification of HRD status using biomarkers allows clinicians to selectively prescribe PARP inhibitors to patients most likely to benefit, improving treatment outcomes.
The global PARP Inhibitor Biomarkers Market is estimated to be valued at US$ 5.62 Bn in 2024 and is expected to exhibit a CAGR of 49.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key Trends:
The increasing adoption of companion diagnostics is a major trend in the PARP inhibitor biomarkers market. Companion diagnostics help identify patients that are likely to respond to a specific therapy, increasing efficacy and minimizing harm from unnecessary treatment. Regulatory agencies now require companion diagnostics to be developed alongside molecularly targeted therapies like PARP inhibitors. Biomarker tests to detect HRD status are being developed and commercialized as companion diagnostics for PARP inhibitors. This is driving the demand for PARP inhibitor biomarkers. Academia-industry partnerships are also playing a key role in the development and validation of new biomarkers. Biopharma companies are collaborating with cancer research institutes to incorporate biomarker stratification in clinical trials. This is expected to translate biomarker research into clinically applicable assays.
Porter’s Analysis
Threat of new entrants: The PARP Inhibitor Biomarkers Market requires high R&D investments and stringent regulatory approvals which pose significant entry barriers for new players.
Bargaining power of buyers: The presence of numerous biomarker testing laboratories gives buyers diverse options and bargaining power in the market.
Bargaining power of suppliers: A few major players dominate the supply of biomarkers and assay kits, giving them strong negotiating power over price and quality.
Threat of new substitutes: New technological advancements may lead to development of novel biomarkers with higher efficacy, replacing existing PARP inhibitor biomarkers.
Competitive rivalry: Major players competitively differentiate their product portfolios based on biomarkers detection methods to gain market share.
Key Takeaways
The global PARP Inhibitor Biomarkers Market is expected to witness high growth at a CAGR of 49% during the forecast period of 2024 to 2031. The market size is projected to reach US$ 5.62 Billion by 2024.
Regional analysis:
North America currently dominates the market owing to availability of advanced healthcare facilities and presence of major players. However, Asia Pacific is expected to grow at the fastest pace during the forecast period due to rising healthcare expenditure and increasing cancer incidence.
Key players:
Key players operating in the PARP Inhibitor Biomarkers Market are BASF SEChembond Chemicals LimitedGE Water and Process TechnologiesKurita Water Industries Ltd.Ion ExchangeKemira OyjAkzoNobel N.V.SolenisThermax Ltd.Veolia Water TechnologiesAccepta Advanced Environmental TechnologiesHubbard-Hall IncBeckart EnvironmentalEcolab Incorporated. Major players are focusing on new product launches and acquisitions to strengthen their market positions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
